Somru Bioscience

What Somru Bioscience does

Somru BioScience Inc. is a privately held Canadian biotechnology company and contract research organization (CRO) headquartered in Charlottetown, Prince Edward Island, with 51-100 employees. Founded in 2012, the company provides integrated drug discovery, preclinical and clinical development, bioanalytical testing, immunogenicity assessment, biomarker analysis, assay development, clinical laboratory services, biosimilar characterization, vaccine development support, and regulatory consulting services to pharmaceutical, biotechnology, vaccine, and government clients worldwide.

The company's core technology stack centers on proprietary platforms including Amplatto™ (ultra-sensitive immunoassay solutions for low-abundance biomarker and impurity detection), Intelli.b™ (platform for comparability testing of biosimilars at the molecular level aligned with FDA guidance for fingerprint-like analysis), Aegyris™, and a chicken antibody technology platform. It complements these with a portfolio of reagent kits covering antibodies, pharmacokinetic assays, immunogenicity ELISA kits, characterization kits, and biomarker kits. The company also offers AI-driven bioanalytics capabilities combined with regulatory expertise to address bioanalytical challenges in biosimilar development.

Somru operates a dual revenue model: (1) CRO professional services delivered directly to enterprise pharma, biotech, vaccine, and government clients globally, and (2) one-time reagent/kit product sales. Distribution is direct-to-enterprise with no disclosed pricing. The company markets through its corporate website, industry conferences (BIO International Convention 2026), and government relations (hosting Canada's Minister of Industry). In June 2026, Somru expanded internationally by acquiring Bangladesh-based Novus Clinical Research Services Limited through its affiliate Somru BioScience (BD) Limited, creating an integrated North America-South Asia clinical research platform.

Name

Somru Bioscience

Legal name

Somru BioScience Inc.

Website

https://somrubioscience.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Somru BioScience is a Canadian CRO and biotechnology company providing integrated drug discovery, preclinical and clinical development, bioanalytical testing, and biosimilar characterization services to pharmaceutical, biotechnology, vaccine, and government clients worldwide, supported by proprietary immunoassay and biosimilar comparability platforms.

Ownership category

akta.pro rank

Product category

Contract Research Organization (Biotechnology CRO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industries

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)

Keywords

• Contract research organization
• Biosimilar development services
• Immunogenicity assay kits
• Biomarker testing solutions
• Antibody technology platform

Headquarters

HQ city

Charlottetown

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Organization Services: Provides comprehensive CRO services including integrated drug discovery, preclinical and clinical development, bioanalytical testing, immunogenicity assessment, biomarker analysis, assay development, clinical laboratory services, biosimilar characterization, vaccine development support, and regulatory consulting services to pharmaceutical, biotechnology, vaccine, and government clients worldwide.
2. Reagent Products and Kits: Offers a portfolio of reagents, tools, and solutions including antibodies, pharmacokinetic kits, immunogenicity kits, characterization kits, and biomarker kits for biosimilar and biopharmaceutical development.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Somru BioScience Inc. is a Canadian biotechnology company and contract research organization (CRO) that provides integrated drug discovery, preclinical and clinical development, bioanalytical testing, immunogenicity assessment, biomarker analysis, assay development, clinical laboratory services, biosimilar characterization, vaccine development support, and regulatory consulting services. The company also sells a portfolio of proprietary reagent products and kits including antibody, pharmacokinetic, immunogenicity, characterization, and biomarker kits, supported by proprietary technology platforms (Amplatto Detection, Intelli.b, Aegyris, and Chicken Antibody).

Product overview

Somru BioScience Inc. is a global biotechnology company and contract research organization (CRO) headquartered in Prince Edward Island, Canada. The company provides an integrated portfolio of reagents, tools, solutions, and services spanning drug discovery, preclinical and clinical development, bioanalytical testing, immunogenicity assessment, biomarker analysis, assay development, clinical laboratory services, biosimilar characterization, vaccine development support, and regulatory consulting. Their core product offerings include Amplatto™ Detection (ultra-sensitive immunoassay platform), Intelli.b™ (biosimilar comparability testing platform), and a range of ELISA and biomarker kits. The company operates as both a product provider and full-service CRO, recently expanding through the acquisition of Novus Clinical Research Services Limited to create an integrated clinical research platform linking North America and South Asia.

Differentiator

Problem solved

Functional benefit

Brands

• Amplatto Detection: Ultra-sensitive immunoassay solutions for low-abundance biomarker and impurity detection
• Intelli.b
• Aegyris
• Chicken Antibody

Products and services

• Amplatto Detection Ultra-sensitive immunoassay solutions for low-abundance biomarker and impurity detection, offering high specificity, accuracy, reliable reproducibility, and streamlined workflows for biopharmaceutical research.
• Intelli.b Platform for comparability testing of biosimilars at the molecular level, meeting the intent of FDA guidance for fingerprint-like analysis.
• Aegyris Proprietary technology platform offered as part of Somru BioScience's technology portfolio.
• Chicken Antibody Platform Proprietary chicken antibody technology platform for specific research and biopharmaceutical applications.
• Antibodies Antibody products for biopharmaceutical research and development applications.
• Pharmacokinetic Kits ELISA kits for pharmacokinetic studies measuring drug concentration and absorption in biological matrices.
• Immunogenicity Kits High-quality, sensitive, and robust off-the-shelf ELISA kits for the measurement of anti-drug antibodies (both anti-innovator and anti-biosimilar) in biological matrices.
• Characterization Kits Kits for biosimilar characterization testing to assess molecular similarity between biosimilars and reference biologics.
• Biomarker Kits Assays for biomarker testing integral to personalized drug development, biosimilar, and biobetter drug development processes.
• Biosimilars Characterization Service Comprehensive CRO services for biosimilar characterization enabling companies to capitalize on biosimilar opportunities with reduced time and cost.
• Custom Antibody Generation Custom antibody generation services tailored to specific research and development needs.
• Data Analysis Data analysis services for bioanalytical testing and research programs.
• Automation & Robotics Automation and robotics services to streamline laboratory workflows.
• Consulting & Technical Advisory Expert consulting and technical advisory services for biopharmaceutical development.

Quantifiable outcome

• Over 90% precision in identifying high-risk antibody candidates (from multi-year research partnership with Boehringer Ingelheim)

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

One partnership is on record.

• Novus Clinical Research Services LimitedcoreStrategic or Co-development Partner · 17 June 2026Somru BioScience Inc., through its Bangladesh affiliate Somru BioScience (BD) Limited, acquired 100% of Bangladesh-based Novus Clinical Research Services Limited. The acquisition aims to create an integrated clinical research platform linking North America and South Asia, combining Somru's AI-driven bioanalytics and regulatory capabilities with Novus's established operations in Bangladesh. The expanded platform is expected to draw more international research projects to Canada's Prince Edward Island while strengthening Bangladesh's role in the global clinical research ecosystem.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• BioAgilytix Labs: Specialized bioanalytical CRO with deep immunogenicity, PK, and biomarker assay capabilities serving pharma and biotech—directly comparable to Somru's Amplatto™ and biomarker/immunogenicity kit business lines.
• Bio-Techne: Manufacturer of research-use antibodies, ELISA kits, and biomarker assay reagents—directly comparable to Somru's antibody, biomarker, immunogenicity, and characterization kit product lines.
• Cell Signaling Technology: Specialty antibody and ELISA kit manufacturer for research and biopharma applications, including biomarker assays—directly comparable to Somru's catalog antibody, PK, immunogenicity, and biomarker kit portfolio.

Broad incumbents

• Charles River Laboratories: Large preclinical and bioanalytical CRO offering discovery through clinical lab services to pharma/biotech, overlapping with Somru's preclinical, bioanalytical, and biosimilar characterization offerings across a much broader portfolio.
• Eurofins Scientific: Global bioanalytical and pharma testing services provider with extensive biosimilar and biopharma product testing capabilities; competes broadly with Somru's bioanalytical and biosimilar characterization services across much larger geographies.
• Sartorius AG: Bioprocessing and analytics incumbent whose bioanalytics instruments and consumables intersect with Somru's assay and reagent business; broader portfolio but overlapping customer base in biopharma development.
• WuXi AppTec: Global CRO/CDMO with extensive bioanalytical and biologics characterization services; competes with Somru in biosimilar comparability, immunogenicity, and biomarker assay services with significantly greater scale and geographic reach.
• Repligen Corporation: Bioprocessing-focused supplier with analytics and immunoassay capability for biologics manufacturing and development; overlaps with Somru's bioanalytical services and Amplatto™ immunoassay positioning in the biopharma workflow.
• IQVIA: Largest global clinical CRO with deep bioanalytical lab services; competes with Somru on integrated drug discovery, clinical development, and bioanalytical engagements for the same pharma and biotech clients.

Emerging players

• AbCellera Biologics: Antibody discovery and engineering platform company with proprietary screening technology; comparable to Somru's chicken antibody platform and custom antibody generation service line, with overlapping pharma customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/somrubio
• LinkedInlinkedin.com/company/somru-bioscience-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Somru Bioscience